Cover Image

Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers

Abstract Olverembatinib (HQP1351) is a BCR‐ABL1 tyrosine kinase inhibitor with promising clinical activity. It is approved in China for the treatment of patients with chronic myeloid leukemia harboring drug‐resistant mutations, such as T315I. In vitro studies suggested that metabolism of olverembati...

Full description

Saved in:
Bibliographic Details
Main Authors: Hengbang Wang (Author), Yun Yang (Author), Zi Chen (Author), Lei Fu (Author), Min Yu (Author), Lixin Jiang (Author), Cunlin Wang (Author), Lichuang Men (Author), Ilisse Minto (Author), Dajun Yang (Author), Yifan Zhai (Author)
Format: Book
Published: Wiley, 2024-09-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items